At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs. As more rare disease therapies come to market, health plans are often evaluating products for conditions they have never…
Daily therapy with a non-vitamin K antagonist oral anticoagulant (NOAC) can dramatically lower the incidence of venous thromboembolism (VTE) in patients with cancer who are at moderate-to-high risk for developing a clot, according to the results of two new studies.
Myeloproliferative Neoplasms (MPNs) are rare hematologic neoplasms. The epidemiology and outcomes of these rare neoplasms warrant an update considering new diagnostic tools and advances in treatment options. NCIâs Surveillance, Epidemiology and End... Thank you for visiting nature.com. You…
“We are excited to collaborate with Stanford Medicine and advance the evaluation of STAR-LLD,” said Pedro Lichtinger, Chairman and CEO. “This agreement represents an important step in our strategy, as we believe this combination has the potential to improve CAR-T…
A phase 3 trial compares ponatinib plus blinatumomab with imatinib plus chemotherapy as first-line treatment for adults with Philadelphia-positive acute lymphoblastic leukemia. Ponatinib Plus Blinatumomab Boosts EFS in Ph-Positive ALL A chemotherapy-free regimen combining ponatinib plus blinatumomab improved event-free survival (EFS)…
When the news came out last month that a New York woman was likely cured of HIV/AIDS by the same cord blood transplant she had received to save her from leukemia, Dr. Filippo Milano’s telephone at Seattle’s Fred Hutchinson…
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center. I have had patients who have received this device vs a shot of the…
Experts at the 2025 ICE-T Symposium reviewed CAR T-cell therapy, bispecific antibodies, and gene therapy across myeloma, lymphoma, autoimmune disease, and solid tumors, emphasizing safety and access. The analysis included 128 patients treated with BCMA-directed CAR T-cell therapy between December 2019 and December…
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with... HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody…
Ali Hargett, a sophomore public health major at the University of Mississippi from Greenwood, Miss., is determined to find a bone marrow donor for her 11-year-old sister, Cate Hargett. Hargett is hosting a National Marrow Donor Program (NMDP) registry drive…
Leukaemia, lymphoma and myeloma: new drugs, CAR-T and bispecifics, research, and the transplants that treat them.
An article joins this feed when it matches these terms. Each one is also a search of its own.